New monoclonal antibody treatments show promise in targeting the inflammatory pathways linked to eczema and asthma, potentially preventing food allergies like peanut allergy. Consistent oral exposure to allergens from an early age is highlighted as the most effective strategy for prevention. However, concerns arise about low-dose allergen exposure through the skin, which may paradoxically increase the risk of developing food allergies.
